Journal of Psoriasis and Psoriatic Arthritis最新文献_第3页

Predicting Psoriatic Arthritis in Psoriasis Patients – A Swiss Registry Study 预测银屑病患者的银屑病关节炎--一项瑞士登记研究

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-11-21 DOI: 10.1177/24755303231217492

Mia‐Louise Nielsen, T. Petersen, L. V. Maul, J. P. Thyssen, S. F. Thomsen, Jashin J. Wu, A. A. Navarini, Thomas Kündig, Nikhil Yawalkar, Christoph Schlapbach, Wolf-Henning Boehncke, Curdin Conrad, Antonio Cozzio, R. Micheroli, Lars Erik Kristensen, Alexander Egeberg, J. Maul

{"title":"Predicting Psoriatic Arthritis in Psoriasis Patients – A Swiss Registry Study","authors":"Mia‐Louise Nielsen, T. Petersen, L. V. Maul, J. P. Thyssen, S. F. Thomsen, Jashin J. Wu, A. A. Navarini, Thomas Kündig, Nikhil Yawalkar, Christoph Schlapbach, Wolf-Henning Boehncke, Curdin Conrad, Antonio Cozzio, R. Micheroli, Lars Erik Kristensen, Alexander Egeberg, J. Maul","doi":"10.1177/24755303231217492","DOIUrl":"https://doi.org/10.1177/24755303231217492","url":null,"abstract":"Psoriatic arthritis (PsA) is a prevalent comorbidity among patients with psoriasis, heavily contributing to their burden of disease, usually diagnosed several years after the diagnosis of psoriasis. To investigate the predictability of psoriatic arthritis in patients with psoriasis and to identify important predictors. Data from the Swiss Dermatology Network on Targeted Therapies (SDNTT) involving patients treated for psoriasis were utilized. A combination of gradient-boosted decision trees and mixed models was used to classify patients based on their diagnosis of PsA or its absence. The variables with the highest predictive power were identified. Time to PsA diagnosis was visualized with the Kaplan-Meier method and the relationship between severity of psoriasis and PsA was explored through quantile regression. A diagnosis of psoriatic arthritis was registered at baseline of 407 (29.5%) treatment series. 516 patients had no registration of PsA, 257 patients had PsA at inclusion, and 91 patients were diagnosed with PsA after inclusion. The model’s AUROCs was up to 73.7%, and variables with the highest discriminatory power were age, PASI, physical well-being, and severity of nail psoriasis. Among patients who developed PsA after inclusion, significantly more first treatment series were classified in the PsA-group, compared to those with no PsA registration. PASI was significantly correlated with the median burden/severity of PsA ( P = .01). Distinguishing between patients with and without PsA based on clinical characteristics is feasible and even predicting future diagnoses of PsA is possible. Patients at higher risk can be identified using important predictors of PsA.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":"28 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139252862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessing Comparative Efficacy of Biologics for the Treatment of Psoriasis With Nail Involvement: A Systematic Review 评估生物制剂治疗指甲受累型银屑病的比较疗效：系统回顾

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-11-18 DOI: 10.1177/24755303231217491

Madiha Khan, Carly E. Wallace, Fahad Ahmed, Syed Minhaj Rahman, Nashwah Memon, Adel Haque

{"title":"Assessing Comparative Efficacy of Biologics for the Treatment of Psoriasis With Nail Involvement: A Systematic Review","authors":"Madiha Khan, Carly E. Wallace, Fahad Ahmed, Syed Minhaj Rahman, Nashwah Memon, Adel Haque","doi":"10.1177/24755303231217491","DOIUrl":"https://doi.org/10.1177/24755303231217491","url":null,"abstract":"Despite recent advances in biologics, there is a lack of significant evidence regarding the comparative efficacy of biologics in treating more resistant features of psoriasis, namely nail psoriasis. A systematic review synthesizing data from multiple studies is efficacious in assessing the comparative efficacy among biologics for the treatment of nail psoriasis. To evaluate and compare the efficacy of biologics for the treatment of nail psoriasis. Utilizing PRISMA guidelines, a systematic literature review was conducted using the Pubmed database on November 16, 2022. Studies selected were phase 3 or 4 randomized clinical trials, clinical studies, or other randomized trials with data on the treatment with biologics for adults with nail psoriasis. Sixteen studies meeting inclusion criteria were included for analysis. At 24 weeks, the highest mean NAPSI percent improvement achieved at week 24 was by brodalumab (76.9%) followed by etanercept (74%) and ixekizumab (70.5%) while the biologics achieving the greatest proportion of NAPSI 0 were adalimumab (44.6%) and ixekizumab (41%). This study helps elucidate the comparative efficacy of biologics for the treatment of nail psoriasis. This review suggests that brodalumab and etanercept are associated with the highest percent improvement in nail psoriasis while adalimumab and ixekizumab are associated with the greatest probability of complete nail resolution.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":"177 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139261323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biosimilars in Dermatology Review 皮肤病学综述中的生物仿制药

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-11-03 DOI: 10.1177/24755303231212154

John Baker, Robert Kalb

{"title":"Biosimilars in Dermatology Review","authors":"John Baker, Robert Kalb","doi":"10.1177/24755303231212154","DOIUrl":"https://doi.org/10.1177/24755303231212154","url":null,"abstract":"Background Safe and effective biosimilar medications have the potential to significantly increase access to these valuable drugs. The two current biosimilars available in dermatology in the United States (US) are infliximab and rituximab which were Food and Drug Administration (FDA) approved in 2016 and 2018 respectively. There has been significant interest in this topic as a number of biosimilar versions of adalimumab will be available in 2023. Objective This review will discuss biosimilar basics and the experience with biosimilars used in dermatology in the US, Asia, and Europe. Methods All articles in Ovid/Medline from 2015 to Feb 2023 on biosimilars were reviewed with a particular emphasis on medications used in dermatology. Other reports from pharmaceutical manufacturers and blogs following the development of the biosimilar industry provided key insights. Results Biosimilars have been able to produce significant savings and market share increases, particularly in Europe, where there has been a longer experience. The specifics depend on drug prescribing practices and incentives in the individual country. This degree of savings and market share increases have not been realized with the current biosimilars available in the US. Conclusion While biosimilars have resulted in significant savings compared to originator drugs, it is clear that prescribing incentives and physician education are crucial in achieving these savings. To what degree biosimilar market share will increase in the US remains to be determined.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":"6 4","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135869241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Influence of Psoriasis on Type 2 Diabetes Mellitus Patient Profiles: A National Inpatient Sample Study 银屑病对2型糖尿病患者的影响:一项全国住院患者样本研究

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-11-02 DOI: 10.1177/24755303231212153

Nilesh Kodali, Isabella Blanchard, Keshav D. Kumar, Mallory Zaino, Steven R. Feldman

{"title":"The Influence of Psoriasis on Type 2 Diabetes Mellitus Patient Profiles: A National Inpatient Sample Study","authors":"Nilesh Kodali, Isabella Blanchard, Keshav D. Kumar, Mallory Zaino, Steven R. Feldman","doi":"10.1177/24755303231212153","DOIUrl":"https://doi.org/10.1177/24755303231212153","url":null,"abstract":"Background Psoriasis is believed to be a common comorbidity of type 2 diabetes mellitus (T2DM). Little is known on the impact psoriasis has on T2DM patients’ disease profiles. Objective To assess the impact psoriasis has on T2DM patients’ demographics, comorbidities, and health care outcomes. Methods We retrospectively analyzed the 2017 U.S. National Inpatient Sample (NIS) database. We utilized ICD-10 codes to determine T2DM and psoriasis patients along with associated comorbidities. Continuous variables were compared by independent-sample t-tests and categorical variables were compared via Pearson chi-square. All analysis were conducted in IBM SPSS 25. Results Among 7,705,988 T2DM admissions, 0.67% of them had comorbid psoriasis. T2DM psoriasis patients (64.38; SD: 12.403) were, on average, younger (64.38 vs 66.73; P < .001) and white (78.7% vs 63.1%; P < .001) and had increased foot ulcers (4.2% vs 3.8%; P < .001), hyperglycemia (22.4% vs 21.0%; P < .001), retinopathy (22.4% vs 21.0%; P < .001), hypercoagulopathy (8.5% vs 6.9%; P < .001), and hypertension (72.5% vs 70.4%; P < .001) than T2DM patients without psoriasis. T2DM psoriasis patients spent more days in the hospital (5.49 vs 5.37; P < .001), had more concurrent diagnoses (19.05 vs 16.5; P < .001), less total charges ($60,596.71 vs $61,534.66; P = 0.010) and had less in-hospital deaths (2.0% vs 2.7%; P < .001) than T2DM patients without psoriasis. Conclusions The presence of comorbid psoriasis significantly impacts T2DM patients’ demographics, comorbidities, and health care outcomes. These findings underscore the importance of early disease monitoring, cross-specialty collaboration, and medication monitoring in order to guide individualized management strategies and optimize patient care.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":"12 5","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135974535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to Acute Respiratory Distress Syndrome in a Carrier of an Interleukin-36 Receptor Antagonist Mutation With Generalized Pustular Psoriasis. 白介素-36受体拮抗剂突变携带者与广泛性脓疱性银屑病急性呼吸窘迫综合征的勘误表

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-10-01 Epub Date: 2023-08-23 DOI: 10.1177/24755303231195868

引用次数: 0

Corrigendum to Antibody Response to BNT162b2 Vaccine in Immune Modifiers-Treated Psoriatic Patients. 免疫调节剂对BNT162b2疫苗的抗体反应更正——治疗银屑病患者

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-10-01 Epub Date: 2023-08-23 DOI: 10.1177/24755303231195874

引用次数: 0

Corrigendum to Prevalence of Utilization Management Policies Among the Psoriatic Disease Community: Results From the 2019 National Psoriasis Foundation Advocacy Survey. 银屑病社区使用管理政策流行情况的勘误表:2019年全国银屑病基金会倡导调查结果

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-10-01 Epub Date: 2023-08-31 DOI: 10.1177/24755303231195870

引用次数: 0

Decrypting Skin Microbiome in Psoriasis: Current Status. 银屑病皮肤微生物组的解密:现状

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-10-01 Epub Date: 2023-08-11 DOI: 10.1177/24755303231194293

Preeti Arya, Manpreet Kaur, Stanzin Chosyang, Neelam Kushwaha, Balvinder Singh

{"title":"Decrypting Skin Microbiome in Psoriasis: Current Status.","authors":"Preeti Arya, Manpreet Kaur, Stanzin Chosyang, Neelam Kushwaha, Balvinder Singh","doi":"10.1177/24755303231194293","DOIUrl":"10.1177/24755303231194293","url":null,"abstract":"Background: Psoriasis is an autoimmune, chronic, inflammatory skin condition of multifactorial etiology. Recent studies in human skin microbiome research have revealed the dysbiosis in lesional skin of psoriatic patients, as well as have established the association of dysbiosis in the elicitation of inflammatory response of psoriatic skin.Objective: The present review aimed to recapitulate the insights of psoriasis lesional skin microbiome studies published in the last 2 decades, and to determine the most important bacterial genera that can be deployed as psoriatic skin microbial signature for therapeutic intervention.Methods: To achieve the stated objectives, full-text analysis of literature selected through systematic search of digital literature databases has been carried out following PRISMA guidelines.Results: Literature analysis suggests differential abundance of specific bacterial genera in the lesional psoriatic skin (LPS) compared to normal skin (NS) of psoriasis patients and skin from healthy subjects. These bacterial genera collectively can be utilized as potential biomarker for constructing lesional psoriatic skin specific microbial signature, and to explore the role of bacterial species in maintaining the skin homeostasis. The analysis further revealed that multiple bacterial species instead of a single bacterial species is important for understanding the psoriasis etiogenesis. Furthermore, decreased microbiome stability and increased diversity might have role in the exacerbation of lesions on skin of psoriatic patients.Conclusion: Considering the importance of human skin microbiome dysbiosis in psoriasis, research efforts should be carried out to develop new therapeutic measures in addition to current therapies by exploiting the human and host-skin-associated microbial genomic and metabolomic knowledge.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"166-178"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361554/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43555639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Serum Adiponectin Levels as an Independent Marker of Severity of Psoriasis: A Cross-Sectional Analysis. 血清脂联素水平作为银屑病严重程度的独立标志物：横断面分析

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-10-01 Epub Date: 2023-08-31 DOI: 10.1177/24755303231199995

Aarushi Kaushik, Dimple Chopra, Karamjot Kaur, Sharang Gupta, Preeyati Chopra

{"title":"Serum Adiponectin Levels as an Independent Marker of Severity of Psoriasis: A Cross-Sectional Analysis.","authors":"Aarushi Kaushik, Dimple Chopra, Karamjot Kaur, Sharang Gupta, Preeyati Chopra","doi":"10.1177/24755303231199995","DOIUrl":"10.1177/24755303231199995","url":null,"abstract":"Background: Adiponectin is an adipokine, having anti-inflammatory properties, the levels of which are reduced in metabolic syndrome. In psoriasis, it plays a preventive role by inhibiting the differentiation and proliferation of keratinocytes and decreasing the levels of the signature cytokine, IL-17.Aims and objectives: To find a correlation between serum adiponectin levels and the severity of psoriasis and to compare these levels amongst patients with parameters of metabolic syndrome vs those without it.Materials and methods: This was a cross-sectional observational study consisting of 60 cases of chronic plaque type psoriasis and 20 controls. Mild, moderate and severe disease was defined based on Psoriasis Area Severity Index (PASI). Serum samples were analyzed for fasting serum adiponectin levels.Results: The mean serum adiponectin level among cases (16.07 ± 8.55 μg/ml) was significantly lower than controls (21.65 ± 8.07 μg/ml, P = .012). It was not only lower among cases with MetS (14.28 ± 7.95 μg/ml), but also in patients without MetS (17.35 ± 8.83 μg/ml). Serum adiponectin levels were negatively correlated to age, Body Mass Index (BMI), PASI, disease duration and Erythrocyte Sedimentation Rate(ESR). However, only the negative correlation with PASI (P = .000), duration (P = .005) and ESR (P = .010), was statistically significant.Conclusion: Serum adiponectin is decreased in psoriasis, independent of metabolic syndrome and is negatively correlated with disease severity and duration.Limitations: Analysis on a larger sample size and response to treatment could not be assessed.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"148-155"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361544/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47033225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to Tildrakizumab Inadequate Responders Switching to an Alternative IL-23 Inhibitor: A Case Series. Tildrakizumab反应不充分转为替代IL-23抑制剂的勘误表：一系列病例

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2023-10-01 Epub Date: 2023-08-31 DOI: 10.1177/24755303231195883

引用次数: 0